stoxline Quote Chart Rank Option Currency Glossary
  
ChromaDex Corporation (CDXC)
3.48  -0.19 (-5.18%)    03-28 16:00
Open: 3.67
High: 3.77
Volume: 486,241
  
Pre. Close: 3.67
Low: 3.18
Market Cap: 262(M)
Technical analysis
2024-03-28 4:50:22 PM
Short term     
Mid term     
Targets 6-month :  4.74 1-year :  5.53
Resists First :  4.05 Second :  4.74
Pivot price 2.81
Supports First :  2.46 Second :  1.48
MAs MA(5) :  3.66 MA(20) :  2.53
MA(100) :  1.68 MA(250) :  1.57
MACD MACD :  0.5 Signal :  0.4
%K %D K(14,3) :  83.9 D(3) :  88.3
RSI RSI(14): 71.7
52-week High :  4.05 Low :  1.25
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CDXC ] has closed below upper band by 27.8%. Bollinger Bands are 594% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 16 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.77 - 3.79 3.79 - 3.81
Low: 3.14 - 3.16 3.16 - 3.18
Close: 3.44 - 3.48 3.48 - 3.51
Company Description

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.

Headline News

Wed, 27 Mar 2024
ChromaDex (NASDAQ:CDXC) Shares Cross Above 200-Day Moving Average of $1.57 - Defense World

Wed, 27 Mar 2024
ChromaDex (NASDAQ:CDXC) Share Price Crosses Above Two Hundred Day Moving Average of $1.57 - MarketBeat

Tue, 26 Mar 2024
2024-03-26 | NDAQ:CDXC | Press Release | Chromadex Corp - Stockhouse Publishing

Mon, 25 Mar 2024
Should Biotechnology Stock Chromadex Corp (CDXC) Be in Your Portfolio Monday? - InvestorsObserver

Mon, 18 Mar 2024
What is the Market's View on Chromadex Corp (CDXC) Stock's Price and Volume Trends Monday? - InvestorsObserver

Thu, 07 Mar 2024
ChromaDex Corporation (NASDAQ:CDXC) Q4 2023 Earnings Call Transcript - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 75 (M)
Shares Float 51 (M)
Held by Insiders 41.1 (%)
Held by Institutions 16 (%)
Shares Short 1,210 (K)
Shares Short P.Month 1,300 (K)
Stock Financials
EPS -0.08
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.37
Profit Margin -6 %
Operating Margin -0.8 %
Return on Assets (ttm) -6.5 %
Return on Equity (ttm) -17.3 %
Qtrly Rev. Growth 1 %
Gross Profit (p.s.) 0
Sales Per Share 1.1
EBITDA (p.s.) -0.07
Qtrly Earnings Growth 0 %
Operating Cash Flow 7 (M)
Levered Free Cash Flow 9 (M)
Stock Valuations
PE Ratio -49.72
PEG Ratio 0
Price to Book value 9.15
Price to Sales 3.13
Price to Cash Flow 36.8
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android